Your SlideShare is downloading. ×
Popular Report: meningococcal vaccines - france drug forecast and market analysis to 2022
Popular Report: meningococcal vaccines - france drug forecast and market analysis to 2022
Popular Report: meningococcal vaccines - france drug forecast and market analysis to 2022
Popular Report: meningococcal vaccines - france drug forecast and market analysis to 2022
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Popular Report: meningococcal vaccines - france drug forecast and market analysis to 2022

204

Published on


PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022
To Read The Complete Report Kindly Visit: http://www.marketresearchreports.biz/analysis/170312
For All Latest Reports Kindly visit: http://www.marketresearchreports.biz

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
204
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022 GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines France Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022. GlobalData does not expect relative patient share to change within the MenC conjugate space because Nuron Biotechs Meningitec, Novartis Menjugate kit, and Baxters NeisVac-C all possess similar clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in France and therefore is not expected to change drastically during the forecast period. The French government has expressed disappointment with the low coverage rates of its MenC immunization program and is expected to renew efforts to expand vaccine use (Stahl et al., 2013). In general, the sales potential in France is derived from the immunization recommendations, which largely determine vaccine usage. Scope Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in France from 2012-2022. Analysis of the impact of key events as well the drivers and restraints affecting France Meningococcal Vaccines market. Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales forecast for drugs from 2012-2022 in France table Of Contents 1 Table Of Contents 1 1.1 List Of Tables 3 1.2 List Of Figures 3 2 Executive Summary 4 2.1 Sales For Meningococcal Vaccine In France 4 2.2 What Do The Physicians Think? 5 PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022
  • 2. 3 Introduction 6 3.1 Catalyst 6 3.2 Related Reports 7 3.3 Upcoming Related Reports 8 4 Disease Overview 9 4.1 Etiology And Pathophysiology 10 4.1.1 Etiology 10 4.1.2 Pathophysiology 11 4.2 Symptoms 13 4.3 Prognosis 14 5 Disease Management 14 5.1 Meningococcal Immunization Policy 15 5.2 France 17 5.2.1 Meningococcal Immunization Recommendations And Policies 17 5.2.2 Clinical Practice 19 6 Competitive Assessment 19 6.1 Overview 19 6.2 Strategic Competitor Assessment 20 6.3 Product Profiles Major Brands 21 6.3.1 Menveo 21 6.3.2 Nimenrix 25 6.3.3 Meningitec 28 6.3.4 Menjugate 31 6.3.5 Neisvac-c 34 6.3.6 Bexsero 37 7 Opportunity And Unmet Need 39 7.1 Overview 39 7.2 Unmet Needs 40 7.2.1 Unmet Need: Protection Against Serogroup B Disease 40 7.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 40 7.2.3 Unmet Need: More Cost-effective Vaccines 42 7.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 43 7.2.5 Unmet Need: Immunogenic Infant Vaccines 44 7.2.6 Unmet Need: Improved Vaccination Coverage Rates 45 7.2.7 Unmet Need: Increased Patient Awareness And Education 46 7.3 Unmet Needs Gap Analysis 47 7.4 Opportunities 48 7.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 48 7.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 49 PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022
  • 3. 7.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging Markets 50 8 Pipeline Assessment 50 8.1 Overview 50 8.2 Promising Vaccines In Clinical Development 50 8.2.1 Mnb Rlp2086 54 8.3 Promising Vaccines In Early Clinical Development 59 8.3.1 Meninge Acyw Conj. 60 8.3.2 Menabcwy 64 8.3.3 Menc Conjugate 67 8.3.4 Heptavalent Dtp-hib-hepb-ipv-menc 70 9 Market Outlook 72 9.1 France 72 9.1.1 Forecast 72 9.1.2 Key Events 76 9.1.3 Drivers And Barriers 77 10 Appendix 78 10.1 Bibliography 78 10.2 Abbreviations 90 10.3 Methodology 92 10.4 Forecasting Methodology 92 10.4.1 Vaccine Coverage 93 10.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 93 10.4.3 Vaccines Included 94 10.4.4 Key Launch Dates 95 10.4.5 General Pricing Assumptions 96 10.4.6 Individual Vaccine Assumptions 97 10.4.7 Pricing Of Pipeline Agents 102 10.5 Physicians And Specialists Included In This Study 103 10.6 About The Authors 107 10.6.1 Authors 107 10.6.2 Reviewers 107 10.6.3 Global Head Of Healthcare 107 10.7 About Globaldata 109 10.8 Contact Us 109 10.9 Disclaimer 109 Market Research Report(http://www.marketresearchreports.biz/) Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022
  • 4. We serve all sizes and types of companies spanning across various industries. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.com Website: www.marketresearchreports.biz PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022

×